Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
25 July 2023 | By CN Bio
The webinar will explore primary concerns in drug discovery development and why drugs fail.
List view / Grid view
25 July 2023 | By CN Bio
The webinar will explore primary concerns in drug discovery development and why drugs fail.
New Salk Institute, US, research could lead to the development of new HIV therapeutics that overcome resistance to existing drugs.
Researchers from Brazil discovered that survival of the parasitic worm that cause the disease schistosomiasis, depends on expression of a specific type of RNA. In animal trials, inhibition of the molecule interrupted the infection.
Professor at Texas Tech University's Department of Biological Sciences has been granted an Innovative Project Award by the American Heart Association to delve into the intricacies of atherosclerosis, a condition responsible for artery thickening and severe health complications.
Australian researchers analyse the way specialised white blood cells produce an immune response, which could lead to the development of preventative treatments for cancer and infectious diseases.
Guidelines unveiled at AAIC 2023 using blood biomarkers offer faster and more effective Alzheimer's diagnosis.
HGPS mouse models were used to test the hypothesis that the accelerated aging typical of progeroid mice is associated with reduced hepatic H2S production.
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.
A US study has overcome a major obstacle in cell-free DNA (cfDNA) testing or liquid biopsy, offering promising advancements in disease diagnosis and monitoring.
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
In the unmet need for effective treatments to alleviate suffering and prevent premature death across the spectrum of genetic diseases, Brent Warner, Poseida Therapeutics, shares that the ability to edit DNA holds hope for patients currently experiencing incurable genetic diseases and has spurred ongoing efforts to develop and improve gene…
US researchers find that recurrent bouts of systemic lupus erythematosus is closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.
Download your FREE ebook, featuring articles about cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and advancements in gene editing.